drugset / Trial / NCT01468987

A Study in Participants With Type 2 Diabetes Mellitus

NCT01468987

Phase 3 Completed 1369 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is: * To compare blood glucose (blood sugar) control on LY2605541 with insulin glargine after 26 weeks of treatment. * To compare the rate of night time hypoglycemia (low blood glucose) on LY2605541 with insulin glargine during 26 weeks of treatment. * To compare the number of participants on LY2605541 reaching blood glucose targets without hypoglycemia episodes at night to those taking insulin glargine after 26 weeks of treatment. * To compare the rate of hypoglycemia over a 24-hour period on LY2605541 with insulin glargine during 26 weeks of treatment.

Timeline

Start
2011-12
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Peglispro Protein / enzyme biologic Subcutaneous
Comparator insulin glargine Protein / enzyme biologic Subcutaneous
Background Insulin Lispro Protein / enzyme biologic Subcutaneous